These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 8764124)

  • 1. Ablation of colorectal xenografts with combined radioimmunotherapy and tumor blood flow-modifying agents.
    Pedley RB; Boden JA; Boden R; Boxer GM; Flynn AA; Keep PA; Begent RH
    Cancer Res; 1996 Jul; 56(14):3293-300. PubMed ID: 8764124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancement of antibody-directed enzyme prodrug therapy in colorectal xenografts by an antivascular agent.
    Pedley RB; Sharma SK; Boxer GM; Boden R; Stribbling SM; Davies L; Springer CJ; Begent RH
    Cancer Res; 1999 Aug; 59(16):3998-4003. PubMed ID: 10463598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eradication of colorectal xenografts by combined radioimmunotherapy and combretastatin a-4 3-O-phosphate.
    Pedley RB; Hill SA; Boxer GM; Flynn AA; Boden R; Watson R; Dearling J; Chaplin DJ; Begent RH
    Cancer Res; 2001 Jun; 61(12):4716-22. PubMed ID: 11406542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts.
    Burke PA; DeNardo SJ; Miers LA; Lamborn KR; Matzku S; DeNardo GL
    Cancer Res; 2002 Aug; 62(15):4263-72. PubMed ID: 12154028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dosimetric evaluation and radioimmunotherapy of anti-tumour multivalent Fab' fragments.
    Casey JL; Pedley RB; King DJ; Green AJ; Yarranton GT; Begent RH
    Br J Cancer; 1999 Nov; 81(6):972-80. PubMed ID: 10576653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer.
    Wong JY; Shibata S; Williams LE; Kwok CS; Liu A; Chu DZ; Yamauchi DM; Wilczynski S; Ikle DN; Wu AM; Yazaki PJ; Shively JE; Doroshow JH; Raubitschek AA
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5842-52. PubMed ID: 14676105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Timing effects of combined radioimmunotherapy and radiotherapy on a human solid tumor in nude mice.
    Sun LQ; Vogel CA; Mirimanoff RO; Coucke P; Slosman DO; Mach JP; Buchegger F
    Cancer Res; 1997 Apr; 57(7):1312-9. PubMed ID: 9102219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative toxicity and efficacy of combined radioimmunotherapy and antiangiogenic therapy in carcinoembryonic antigen-expressing medullary thyroid cancer xenograft.
    Kraeber-Bodéré F; Bodet-Milin C; Niaudet C; Saï-Maurel C; Moreau A; Faivre-Chauvet A; Thomare P; Deleris G; Estieu-Gionnet K; Bikfalvi A; Barbet J; Paris F
    J Nucl Med; 2010 Apr; 51(4):624-31. PubMed ID: 20351352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
    Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
    Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature.
    Tijink BM; Neri D; Leemans CR; Budde M; Dinkelborg LM; Stigter-van Walsum M; Zardi L; van Dongen GA
    J Nucl Med; 2006 Jul; 47(7):1127-35. PubMed ID: 16818947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined radioimmunotherapy and radiotherapy of human colon carcinoma grafted in nude mice.
    Buchegger F; Rojas A; Delaloye AB; Vogel CA; Mirimanoff RO; Coucke P; Sun LQ; Raimondi S; Denekamp J; Pèlgrin A
    Cancer Res; 1995 Jan; 55(1):83-9. PubMed ID: 7805046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined radioimmunotherapy and chemotherapy of human colon carcinoma grafted in nude mice, advantages and limitations.
    Chalandon Y; Mach JP; Pèlegrin A; Folli S; Buchegger F
    Anticancer Res; 1992; 12(4):1131-9. PubMed ID: 1503403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment with the tumor necrosis factor-alpha-inducing drug 5,6-dimethylxanthenone-4-acetic acid enhances the antitumor activity of the photodynamic therapy of RIF-1 mouse tumors.
    Bellnier DA; Gollnick SO; Camacho SH; Greco WR; Cheney RT
    Cancer Res; 2003 Nov; 63(22):7584-90. PubMed ID: 14633671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pretargeted radioimmunotherapy of human colorectal xenografts with bispecific antibody and 131I-labeled bivalent hapten.
    Gautherot E; Rouvier E; Daniel L; Loucif E; Bouhou J; Manetti C; Martin M; Le Doussal JM; Barbet J
    J Nucl Med; 2000 Mar; 41(3):480-7. PubMed ID: 10716323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benefits of combined radioimmunotherapy and anti-angiogenic therapy in a liver metastasis model of human colon cancer cells.
    Li XF; Kinuya S; Yokoyama K; Koshida K; Mori H; Shiba K; Watanabe N; Shuke N; Michigishi T; Tonami N
    Eur J Nucl Med Mol Imaging; 2002 Dec; 29(12):1669-74. PubMed ID: 12458402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Influence of combination of low dosage 131I-labeled anti-carcinoembryonic antigen antibody C50 and 5-fluorouracil on tumor growth of colorectal cancer xenografts in nude mice].
    Zheng CX; Zhan WH; Cai SR; He YL; Lin ZJ
    Ai Zheng; 2003 Apr; 22(4):354-7. PubMed ID: 12703987
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radioimmunotherapy of colorectal cancer in small volume disease and in an adjuvant setting: preclinical evaluation in comparison to equitoxic chemotherapy and initial results of an ongoing phase-I/II clinical trial.
    Behr TM; Memtsoudis S; Vougioukas V; Liersch T; Gratz S; Schmidt F; Lorf T; Post S; Wörmann B; Hiddemann W; Ringe B; Becker W
    Anticancer Res; 1999; 19(4A):2427-32. PubMed ID: 10470170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor vascular response to photodynamic therapy and the antivascular agent 5,6-dimethylxanthenone-4-acetic acid: implications for combination therapy.
    Seshadri M; Spernyak JA; Mazurchuk R; Camacho SH; Oseroff AR; Cheney RT; Bellnier DA
    Clin Cancer Res; 2005 Jun; 11(11):4241-50. PubMed ID: 15930363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
    Wong JYC ; Chu DZ; Yamauchi DM; Williams LE; Liu A; Wilczynski S; Wu AM; Shively JE; Doroshow JH; Raubitschek AA
    Clin Cancer Res; 2000 Oct; 6(10):3855-63. PubMed ID: 11051230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toxicity and efficacy of radioimmunotherapy in carcinoembryonic antigen-producing medullary thyroid cancer xenograft: comparison of iodine 131-labeled F(ab')2 and pretargeted bivalent hapten and evaluation of repeated injections.
    Kraeber-Bodéré F; Faivre-Chauvet A; Saï-Maurel C; Campion L; Fiche M; Gautherot E; Le Boterff J; Barbet J; Chatal JF; Thédrez P
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3183s-3189s. PubMed ID: 10541362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.